1187.5000 7.60 (0.64%)
NSE Jun 16, 2026 14:44 PM
Volume: 17,201
 

1187.50
0.64%
Deven Choksey
We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 28x FY28E and we value the company at a PE of 32x FY28E EPS, implying a target price of INR 1,426 with the upside of 12.2%.
Tatva Chintan Pharma has gained 25.69% in the last 1 Year
More from Tatva Chintan Pharma Chem Ltd.
Recommended